Results 41 to 50 of about 14,957,077 (381)

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco, Maffini, Enrico, Saraceni, Francesco   +2 more
core   +1 more source

CAR-T cell. the long and winding road to solid tumors [PDF]

, 2018
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the "next generation" of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment ...
A Heczey, AH Long, AM Leen, AP Cogdill, ARW Schröder, B Clémenceau, B Moldt, BD Koster, C Carpenito, C Zhang, CE Brown, CH June, CM Bollard, D Kobelt, DM Frey, DM Pardoll, DM Shayakhmetov, DW Lee, EI Buchbinder, EJ Lipson, EM Allen Van, F Bushman, F Ochi, F You, FS Hodi, G Gross, G Sconocchia, G Sconocchia, GL Beatty, H Karlsson, H Koehler, H Torikai, HC Ertl, HJ Pegram, I Caruana, J Badhiwala, J Ellis, J Wang, JE Bakema, JH Sampson, JL Tanyi, K Kono, K Kono, K Kudo, K Tamada, K Töpfer, KC Feng, L Bracci, L Zhang, LE Kandalaft, LM Rogers, LM Whilding, M Chmielewski, M Hegde, M Koneru, M Palma De, M Sadelain, M Sadelain, MA Ligtenberg, MC Milone, MCI Schalkwyk van, MD Stewart, ME Mikucki, ME Weijtens, MJ Besser, MJ Besser, MJ Butte, MJ Osborn, ML Davila, ML Davila, MM D’Aloia, MV Maus, N Ahmed, N Ahmed, O Walisko, P Kebriaei, PB Hackett, PC Schuberth, R Braster, R Monjezi, RA Morgan, RA Morgan, RJ Brentjens, RP Junghans, S Chabot, S Mohammed, S Nayak, S Sakaguchi, S Su, S Toyokuni, S Wilkie, SA Richman, SC Katz, SL Goff, SL Maude, SR Witting, SV Kulemzin, TR Medler, TR Simpson, V Arumugam, VD Fedorov, VD Sadelain, W Wang, XS Zhong, Z Eshhar, Z Grada, Z Wang   +106 more
core   +2 more sources

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation

Journal of Hematology & Oncology, 2019
Background Chimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the potential of optimizing the durability
Hejin Jia, Zhenguang Wang, Yao Wang, Yang Liu, Hanren Dai, Chuan Tong, Yelei Guo, Bo Guo, Dongdong Ti, Xiao Han, Qingming Yang, Zhiqiang Wu, Weidong Han   +12 more
doaj   +1 more source

Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel

Frontiers in Immunology, 2022
Chimeric antigen receptor (CAR) T cell therapy is a potent new treatment option for relapsed or refractory hematologic malignancies. As the monitoring of CAR T cell kinetics can provide insights into the activity of the therapy, appropriate CAR T cell ...
Andreas Peinelt, Andreas Peinelt, Melanie Bremm, Melanie Bremm, Hermann Kreyenberg, Hermann Kreyenberg, Claudia Cappel, Claudia Cappel, Julia Banisharif-Dehkordi, Julia Banisharif-Dehkordi, Stephanie Erben, Stephanie Erben, Eva Rettinger, Eva Rettinger, Andrea Jarisch, Andrea Jarisch, Roland Meisel, Paul-Gerhardt Schlegel, Olaf Beck, Gesine Bug, Jan-Henning Klusmann, Thomas Klingebiel, Sabine Huenecke, Sabine Huenecke, Peter Bader, Peter Bader   +25 more
doaj   +1 more source

Novel allogeneic CAR T-cell platform involving microhomology-mediated end joining repair and low off-targeting potential

Molecular Therapy: Nucleic Acids
Several allogeneic chimeric antigen receptor (CAR) T-cell therapies in clinical trials rely on CRISPR-Cas genome editing, but the enzyme’s random repair mechanism increases the risk of undesired off-target effects, challenging safe CAR T-cell generation.
Tanya Hundal, Yan Luo, Yaqing Qie, Martha E. Gadd, Andrew D. Brim, Isas Vazquez-Rosario, Shaohua Guo, Mohamed A. Kharfan-Dabaja, Hong Qin   +8 more
doaj   +1 more source

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV

Frontiers in Immunology, 2019
Re-directing T cells via chimeric antigen receptors (CARs) was first tested in HIV-infected individuals with limited success, but these pioneering studies laid the groundwork for the clinically successful CD19 CARs that were recently FDA approved.
Gloria B. Kim, Kristen Hege, James L. Riley   +2 more
doaj   +1 more source

Donor T cells for CAR T cell therapy

Biomarker Research, 2022
Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed.
Tiffany C. Y. Tang, Ning Xu, Robert Nordon, Michelle Haber, Kenneth Micklethwaite, Alla Dolnikov   +5 more
doaj   +1 more source

Equal opportunity CAR T cells [PDF]

Blood, 2017
In this issue of Blood, Gardner et al report results of a phase 1 trial of 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL) who received a T-cell product of defined CD4/CD8 composition that was genetically modified with a CD19-4-1BB:ζ chimeric antigen receptor (CAR) lentiviral vector ...
Rayne H. Rouce, Helen E. Heslop
openaire   +2 more sources

5G connected and automated driving: use cases, technologies and trials in cross-border environments

EURASIP Journal on Wireless Communications and Networking, 2021
Cooperative, connected and automated mobility (CCAM) across Europe requires harmonized solutions to support cross-border seamless operation. The possibility of providing CCAM services across European countries has an enormous innovative business ...
Dirk Hetzer, Maciej Muehleisen, Apostolos Kousaridas, Sokratis Barmpounakis, Stefan Wendt, Kurt Eckert, Andreas Schimpe, Johan Löfhede, Jesus Alonso-Zarate   +8 more
doaj   +1 more source

Driving CAR T-cells forward [PDF]

Nature Reviews Clinical Oncology, 2016
The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the treatment of patients with cancer showed modest results, but the impressive outcomes of several trials of CD19-targeted CAR T cells in the treatment of patients with B ...
Hollie J, Jackson, Sarwish, Rafiq, Renier J, Brentjens   +2 more
openaire   +2 more sources